Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy

Cytotherapy

Volumn 16, Issue 5, 2014, Pages 619-630

  Barrett, David M ^b   Singh, Nathan ^a   Liu, Xiaojun ^a   Jiang, Shuguang ^a   June, Carl H ^a   Grupp, Stephan A ^b   Zhao, Yangbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

CD19; Chimeric antigen receptor; Leukemia; T lymphocytes; T cell memory

Indexed keywords

CD137 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; OKT 3;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL EXPANSION; CELL ISOLATION; CELL THERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LEUKEMIA; LONG TERM SURVIVAL; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROVOCATION TEST; T CELL CULTURE; TELOMERE; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL LINE; IMMUNOLOGY; IN SITU HYBRIDIZATION; METABOLISM; PROCEDURES; T LYMPHOCYTE; XENOGRAFT;

ANIMALIA;

ANIMALS; ANTIGENS, CD19; CELL LINE; CELLS, CULTURED; HETEROGRAFTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; IN SITU HYBRIDIZATION; LEUKEMIA; MICE; T-LYMPHOCYTES;

EID: 84897960533     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.10.013     Document Type: Article

References (44)

1. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004, 173:7125-7130.
2. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
3. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect oftransferred T cells. Proc Natl Acad Sci U S A 2002, 99:16168-16173.
4. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
5. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
6. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 2011, 3:95ra73.
7. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
8. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003, 3:666-675.
9. Powell D.J., Dudley M.E., Robbins P.F., Rosenberg S.A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005, 105:241-250.
10. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005, 115:1616-1626.
11. Bouneaud C., Garcia Z., Kourilsky P., Pannetier C. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med 2005, 201:579-590.
12. Stemberger C., Neuenhahn M., Gebhardt F.E., Schiemann M., Buchholz V.R., Busch D.H. Stem cell-like plasticity of naive and distinct memory CD8+ T cell subsets. Semin Immunol 2009, 21:62-68.
13. Harris N.L., Watt V., Ronchese F., Le Gros G. Differential Tcell function and fate in lymph node and nonlymphoid tissues. J Exp Med 2002, 195:317-326.
14. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305.
15. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4:225-234.
16. Klebanoff C.A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A.R., Finkelstein S.E., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005, 102:9571-9576.
17. June C.H. Principles of adoptive T cell cancer therapy. J Clin Invest 2007, 117:1204-1212.
18. Riddell S.R., Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990, 128:189-201.
19. Yang S., Dudley M.E., Rosenberg S.A., Morgan R.A. A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother 2010, 33:648-658.
20. Yang S., Ji Y., Gattinoni L., Zhang L., Yu Z., Restifo N.P., et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother 2013, 62:727-736.
21. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol Today 1994, 15:321-331.
22. Levine B.L., Ueda Y., Craighead N., Huang M.L., June C.H. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995, 7:891-904.
23. Levine B.L., Bernstein W.B., Connors M., Craighead N., Lindsten T., Thompson C.B., et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in theabsence of exogenous feeder cells. J Immunol 1997, 159:5921-5930.
24. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009, 106:3360-3365.
25. Parry R.V., Rumbley C.A., Vandenberghe L.H., June C.H., Riley J.L. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol 2003, 171:166-174.
26. Baerlocher G.M., Lansdorp P.M. Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry A 2003, 55:1-6.
27. Baerlocher G.M., Vulto I., de Jong G., Lansdorp P.M. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 2006, 1:2365-2376.
28. Batliwalla F.M., Damle R.N., Metz C., Chiorazzi N., Gregersen P.K. Simultaneous flow cytometric analysis of cell surface markers and telomere length: analysis of human tonsilar B cells. J Immunol Methods 2001, 247:103-109.
29. Spyridopoulos I., Hoffmann J., Aicher A., Brummendorf T.H., Doerr H.W., Zeiher A.M., et al. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation 2009, 120:1364-1372.
30. Barrett D.M., Seif A.E., Carpenito C., Teachey D.T., Fish J.D., June C.H., et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 2011, 118:e112-e117.
31. Barrett D.M., Zhao Y., Liu X., Jiang S., Carpenito C., Kalos M., et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011, 22:1575-1586.
32. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of Tcells and increased antileukemic efficacy in vivo. Mol Ther 2009, 17:1453-1464.
33. Barrett D.M., Liu X., Jiang S., June C.H., Grupp S.A., Zhao Y. Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia. Hum Gene Ther 2013, 24:717-727.
34. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
35. Aubert G., Hills M., Lansdorp P.M. Telomere length measurement-caveats and a critical assessment of the available technologies and tools. Mutat Res 2012, 730:59-67.
36. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
37. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., La Perle K., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007, 13:5426-5435.
38. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45.
39. Finney H.M., Akbar A.N., Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004, 172:104-113.
40. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
41. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
42. Paulos C.M., Carpenito C., Plesa G., Suhoski M.M., Varela-Rohena A., Golovina T.N., et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med 2010, 2:55ra78.
43. Wang X., Naranjo A., Brown C.E., Bautista C., Wong C.W., Chang W.C., et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 2012, 35:689-701.
44. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J clin Oncol 2008, 26:5233-5239.